Cited 0 times in
Comparison of the Prognostic Outcome between High-Grade Ovarian Sertoli-Leydig Cell Tumors (SLCTs) and Low-Grade SLCTs
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김영태 | - |
dc.contributor.author | 김혜민 | - |
dc.contributor.author | 박준식 | - |
dc.contributor.author | 어경진 | - |
dc.date.accessioned | 2021-04-29T17:38:21Z | - |
dc.date.available | 2021-04-29T17:38:21Z | - |
dc.date.issued | 2021-04 | - |
dc.identifier.issn | 0513-5796 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/182444 | - |
dc.description.abstract | The purpose of the current study was to compare prognostic outcomes between patients with high-grade ovarian Sertoli-Leydig cell tumors (SLCTs) and those with other low-grade SLCTs. We retrospectively reviewed medical records for 24 patients pathologically diagnosed with SLCTs between 2006 to 2019 at two institutions. The patients were grouped according to pathological grade: SLCT was classified as grade 1, well differentiated; grade 2, intermediated differentiated; or grade 3, poorly differentiated (Meyer's classification). Statistical analysis was performed to compare survival outcomes according to pathological grade. The median patient age was 42.5 years (range 16-75). Eighteen patients (75%) were International Federation of Gynecology and Obstetrics stage I, and none were diagnosed in stage IV. Nine patients (37.5%) were grade 3, and 15 patients (63.5%) were grades 1-2. When comparing clinical baseline characteristics of the grade 1-2 group with those of the grade 3 group, only serum CA125 level at diagnosis was significantly higher in the grade 3 group (38.34 vs. 382.29, p=0.002). Five patients experienced recurrence of grade 3 disease, while no recurrence was reported in grade 1-2 disease. Four of the five recurrent patients died. In result, grade 3 ovarian SLCT showed significantly poorer prognosis than grade 1-2 disease (overall survival, hazard ratio=14.25, 95% confidence interval=1.881-108.0; log-rank p=0.010). Our findings were consistent with the concept that patients with stage I/grade 1-2 tumors have a good prognosis without adjuvant chemotherapy. Since grade 3 ovarian SLCT appears to be relatively more fatal than grade 1 or 2, patients with grade 3 SLCT might require more aggressive surgical intervention and post-treatment surveillance. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Yonsei University | - |
dc.relation.isPartOf | YONSEI MEDICAL JOURNAL | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Comparison of the Prognostic Outcome between High-Grade Ovarian Sertoli-Leydig Cell Tumors (SLCTs) and Low-Grade SLCTs | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Obstetrics and Gynecology (산부인과학교실) | - |
dc.contributor.googleauthor | Kyung Jin Eoh | - |
dc.contributor.googleauthor | Junsik Park | - |
dc.contributor.googleauthor | Hye Min Kim | - |
dc.contributor.googleauthor | Maria Lee | - |
dc.contributor.googleauthor | Young Tae Kim | - |
dc.identifier.doi | 10.3349/ymj.2021.62.4.366 | - |
dc.contributor.localId | A00729 | - |
dc.contributor.localId | A04553 | - |
dc.contributor.localId | A05788 | - |
dc.contributor.localId | A04842 | - |
dc.relation.journalcode | J02813 | - |
dc.identifier.eissn | 1976-2437 | - |
dc.identifier.pmid | 33779091 | - |
dc.subject.keyword | Ovarian Sertoli-Leydig cell tumors | - |
dc.subject.keyword | chemotherapy | - |
dc.subject.keyword | prognosis | - |
dc.contributor.alternativeName | Kim, Young Tae | - |
dc.contributor.affiliatedAuthor | 김영태 | - |
dc.contributor.affiliatedAuthor | 김혜민 | - |
dc.contributor.affiliatedAuthor | 박준식 | - |
dc.contributor.affiliatedAuthor | 어경진 | - |
dc.citation.volume | 62 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 366 | - |
dc.citation.endPage | 369 | - |
dc.identifier.bibliographicCitation | YONSEI MEDICAL JOURNAL, Vol.62(4) : 366-369, 2021-04 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.